IP Library › Granted Patent US 12,269,866
Granted Patent B2
US 12,269,866 · App. 18/504,534 · Granted Apr 8, 2025

Compositions and methods for the treatment of carboxyhemoglobinemia

Inventors: Mark T. Gladwin (Baltimore, MD); Jesus Tejero Bravo (Pittsburgh, PA)
Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
C07K14/795A61K9/0019A61K38/41A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,269,866
App. No.
18/504,534
Granted
Apr 8, 2025
Kind
B2
Abstract

Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization.

Claims (28)

1. A human recombinant cytoglobin comprising a mutation at residue 81, and further comprising at least one of a C38S mutation and a C83S mutation.

2. The human recombinant cytoglobin of claim 1 , wherein the human recombinant cytoglobin comprises the amino acid sequence of SEQ ID NO: 6.

3. The human recombinant cytoglobin of claim 1 , wherein the human recombinant cytoglobin has a solubility that is superior to the solubility of wild type cytoglobin.

4. The human recombinant cytoglobin of claim 1 , wherein the human recombinant cytoglobin is in monomeric form.

5. The human recombinant cytoglobin of claim 1 , wherein the mutation at residue 81 of the human recombinant cytoglobin is one of a H81Q mutation, a H81A mutation, a H81L mutation, and a H81W mutation.

6. A pharmaceutical composition comprising:

a human recombinant cytoglobin comprising a mutation at residue 81, and further comprising at least one of a C38S mutation and a C83S mutation; and

a pharmaceutically acceptable carrier.

7. The pharmaceutical composition of claim 6 , wherein the human recombinant cytoglobin comprises the amino acid sequence of SEQ ID NO: 6.

8. The pharmaceutical composition of claim 6 , wherein the human recombinant cytoglobin has a solubility that is superior to the solubility of wild type cytoglobin.

9. The pharmaceutical composition of claim 6 , wherein the human recombinant cytoglobin is in monomeric form.

10. The pharmaceutical composition of claim 6 , wherein the mutation at residue 81 of the human recombinant cytoglobin is one of a H81Q mutation, a H81A mutation, a H81L mutation, and a H81W mutation.

11. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is configured for administration by intravenous infusion.

12. The pharmaceutical composition of claim 6 comprising about 50 grams to about 800 grams of the human recombinant cytoglobin.

13. The pharmaceutical composition of claim 6 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of a wetting agent, an emulsifying agent, a preservative, and a pH buffering agent.

14. The pharmaceutical composition of claim 6 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of sodium acetate and sorbitan monolaurate.

15. A method of removing carbon monoxide from hemoglobin in blood or tissue, the method comprising contacting the blood or tissue with a human recombinant cytoglobin having:

a mutation at residue 81, and

at least one of a C38S mutation and a C83S mutation,

thereby removing carbon monoxide from hemoglobin in the blood or tissue.

16. The method of claim 15 , wherein the mutation at residue 81 of the human recombinant cytoglobin is one of a H81Q mutation, a H81A mutation, a H81L mutation, and a H81W mutation.

17. The method of claim 15 , wherein the human recombinant cytoglobin comprises the amino acid sequence of SEQ ID NO: 6.

18. The method of claim 15 , wherein the human recombinant cytoglobin has a solubility that is superior to the solubility of wild type cytoglobin.

19. The method of claim 15 , wherein the human recombinant cytoglobin is in monomeric form.

20. The method of claim 15 , which is an in vivo method, wherein contacting the blood or tissue with a human recombinant cytoglobin comprises administering the human recombinant cytoglobin to a subject.

21. The method of claim 20 , wherein the subject has at least 3%, at least 5%, at least 10%, at least 15% or at least 20% carboxyhemoglobin in their blood.

22. The method of claim 20 , wherein the human recombinant cytoglobin molecule is administered by intravenous infusion.

23. The method of claim 20 , wherein the human recombinant cytoglobin molecule is administered in an amount of about 50 grams to about 800 grams.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2023
From: GLADWIN, MARK T.; BRAVO, JESUS TEJERO
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 065500/0414 →
Continuity (7)
Continuation 16951529 · Nov 18, 2020
Continuation 16557168 · Aug 30, 2019
Continuation 15726779 · Oct 6, 2017
Continuation 14776363
Provisional Application 61834035 · Jun 12, 2013
Provisional Application 61799155 · Mar 15, 2013
Related Publication 20240083979A1 · Mar 14, 2024
References Cited (22)
US 20100323029A1 · Gladwin et al. · 2010 [cited by applicant]
US 20110312914A1 · Kano et al. · 2011 [cited by applicant]
US 20160039910A1 · Gladwin et al. · 2016 [cited by applicant]
US 20180118810A1 · Gladwin et al. · 2018 [cited by applicant]
US 20190389937A1 · Gladwin et al. · 2019 [cited by applicant]
CN 102743456 · 2012 [cited by applicant]
Astudillo et al., Conformational Dynamics in Human Neuroglobin: Effect of His64, Val68, and Cys120 on Ligand Migration, [cited by applicant]
Bocahut et al., “Heme Orientation Modulates Histidine Dissociation and Ligand Binding Kinetics in the Hexacoordinated Human Neuroglobin,” [cited by applicant]
Casado et al., “Human Neuroglobin Protein in Cerebrospinal Fluid,” [cited by applicant]
Gabba et al., “CO Rebinding Kinetics and Molecular Dynamics Simulations Highlight Dynamic Regulation of Internal Cavities in Human Cytoglobin,” [cited by applicant]
Extended European Search Report for EP App. No. 18188514.6, mailed by the European Patent Office on Feb. 5, 2019 (5 pages). [cited by applicant]
Hampson et al., “Practice Recommendations in the Diagnosis, Management, and Prevention of Carbon Monoxide Poisoning,” [cited by applicant]
Kitagishi et al., “A Diatomic Molecule Receptor that Removes CO in a Living Organism,” [cited by applicant]
Makino et al., “Crystal Structure of the Carbon Monoxide Complex of Human Cytoglobin,” [cited by applicant]
MD Nexus, Carboxyhemoglobinemia, Sep. 2, 2012. [cited by applicant]
Nienhaus et al., “Structural Dynamics in the Active Site of Murine Neuroglobin and Its Effects on Ligand Binding,” [cited by applicant]
Raub and Benignus, “Carbon Monoxide and the Nervous System,” [cited by applicant]
Sawai et al., “Structural Characterization of the Proximal and Distal Histidine Environment of Cytoglobin and Neuroglobin,” [cited by applicant]
Tiso et al., “Human Neuroglobin Functions as a Redox-regulated Nitrite Reductase,” [cited by applicant]
Weaver, “Carbon Monoxide Poisoning,” [cited by applicant]
Zhang et al., “Molecular dynamics simulation of carboxy and deoxy human cytoglobin in solution.” [cited by applicant]
Zhang et al., “Neuroglobin, a Novel Intracellular Hexa-Coordinated Globin, Functions as a Tumor Suppressor in Hepatocellular Carcinoma via Raf/MAPK/Erk,” [cited by applicant]